Financial Performance - The company's operating revenue for Q1 2025 was ¥1,242,455,243.50, a decrease of 1.97% compared to ¥1,267,462,044.57 in the same period last year[3] - Net profit attributable to shareholders was ¥223,629,434.88, reflecting a slight increase of 1.29% from ¥220,789,398.54 year-on-year[3] - Basic earnings per share rose to ¥0.34, up 3.03% from ¥0.33 in the same period last year[3] - Net profit for Q1 2025 was CNY 223,629,434.88, an increase of 1.3% compared to CNY 220,789,398.54 in Q1 2024[17] - The net profit attributable to the parent company's shareholders for the current period is CNY 223,629,434.88, compared to CNY 220,789,398.54 in the previous period, reflecting a slight increase[18] - The total comprehensive income for the current period is CNY 223,629,434.88, consistent with the net profit attributable to the parent company[18] Cash Flow - The net cash flow from operating activities decreased significantly by 69.43%, amounting to ¥90,533,209.57 compared to ¥296,176,607.65 in the previous year[3] - Cash flow from operating activities for the current period is CNY 90,533,209.57, a significant decrease from CNY 296,176,607.65 in the previous period[21] - Cash inflow from investment activities is CNY 1,598,445,580.50, compared to CNY 1,220,157,795.45 in the previous period, indicating a strong performance in this area[21] - The net cash flow from investment activities is CNY 10,032,671.59, a recovery from a negative CNY 426,192,878.57 in the previous period[22] - The net increase in cash and cash equivalents for the current period is CNY 104,408,670.45, contrasting with a decrease of CNY 124,950,594.87 in the previous period[22] - The ending balance of cash and cash equivalents is CNY 989,590,032.16, down from CNY 1,161,950,132.81 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥10,173,365,821.62, showing a slight increase of 0.33% from ¥10,140,009,365.84 at the end of the previous year[4] - Total current assets as of March 31, 2025, were CNY 6,054,844,132.51, slightly up from CNY 5,980,458,741.73 as of December 31, 2024[14] - Total non-current assets decreased to CNY 4,118,521,689.11 from CNY 4,159,550,624.11 as of December 31, 2024[14] - Total liabilities as of March 31, 2025, were CNY 1,943,079,956.55, down from CNY 2,132,239,675.29 as of December 31, 2024[15] - The company reported a decrease in accounts payable to CNY 776,475,750.05 from CNY 903,594,044.08[14] Shareholder Information - Shareholders' equity attributable to shareholders increased by 2.78%, reaching ¥8,230,285,865.07 compared to ¥8,007,769,690.55 at the end of the last year[4] - Shareholders' equity increased to CNY 8,230,285,865.07 as of March 31, 2025, compared to CNY 8,007,769,690.55 as of December 31, 2024[15] - The number of ordinary shareholders at the end of the reporting period was 70,488[6] Expenses and Gains - Total operating costs for Q1 2025 were CNY 982,600,179.31, down 2.1% from CNY 1,004,324,485.10 in Q1 2024[17] - Research and development expenses in Q1 2025 amounted to CNY 49,680,967.32, up 24.4% from CNY 39,921,990.72 in Q1 2024[17] - The company reported a total of ¥9,442,163.87 in non-recurring gains and losses for the period[5] - Investment income saw a significant increase of 104.13%, attributed to the maturity income from structured deposits[5] - The company experienced a 39.39% rise in financial expenses due to decreased interest income and exchange gains[5] Accounting Standards - The company has not reported any net profit from subsidiaries prior to consolidation for the current or previous periods[18] - The company is not applying new accounting standards or interpretations for the current reporting period[22]

Financial Performance - The company's operating revenue for 2024 reached CNY 5,125,270,640.68, representing a 2.87% increase compared to CNY 4,982,198,167.78 in 2023[21] - Net profit attributable to shareholders for 2024 was CNY 942,991,305.41, marking a 21.55% increase from CNY 775,802,014.62 in the previous year[21] - The net cash flow from operating activities for 2024 was CNY 1,165,050,367.90, an increase of 11.17% from CNY 1,047,982,969.39 in 2023[21] - The total assets at the end of 2024 amounted to CNY 10,140,009,365.84, an 8.81% increase from CNY 9,318,721,550.84 in 2023[21] - The company's net assets attributable to shareholders reached CNY 8,007,769,690.55 at the end of 2024, reflecting a 6.28% increase from CNY 7,534,508,778.17 in 2023[21] - Basic earnings per share for 2024 were CNY 1.42, a 21.37% increase compared to CNY 1.17 in 2023[22] - The weighted average return on equity for 2024 was 12.09%, up from 10.73% in 2023[22] Operational Efficiency - The company experienced a 16.83% reduction in customer complaint rates and a 33.08% increase in changeover efficiency due to the implementation of lean management practices[31] - The company reported a 57.4% reduction in failure rates, showcasing improvements in production stability and operational efficiency[31] - The company achieved ultra-low emissions standards for all kilns and transitioned to proactive pollution reduction measures, significantly lowering environmental costs per ton of glass[36][37] - The company has implemented a comprehensive safety management system, with over 6,100 employees participating in safety training programs in 2024[38] Product Development and Innovation - The introduction of an AI-powered inspection system in 2024 significantly enhanced product quality detection capabilities, improving detection efficiency and accuracy[32] - The company successfully developed new products such as medical synthetic polyisoprene gaskets and halogenated butyl rubber stoppers, which are expected to enhance profit margins and market competitiveness[34] - In 2024, the company applied for 49 patents and received authorization for 40 patents, including 4 invention patents, showcasing significant achievements in technological innovation[35] Market Position and Strategy - The company’s international market share for main products, including brown bottles and molded bottles, has increased, driven by quality and supply chain advantages[29] - The company is a leading player in the pharmaceutical glass industry, alongside major competitors such as Gerresheimer and Schott, which dominate the market share[48] - The company employs a direct sales and distribution model to leverage its brand and price advantages in the domestic market while actively expanding into international markets[56] Regulatory Environment - The National Medical Products Administration (NMPA) issued a notice on July 16, 2019, clarifying the association review and approval of raw materials and packaging materials related to drug formulations[41] - The revised Drug Administration Law implemented on December 1, 2019, mandates that the NMPA reviews chemical raw materials and related packaging materials together with drug formulations[41] - The NMPA's announcement on July 2019 established that drug formulation approvals indicate that associated raw materials have passed technical reviews, with registration status marked as "A"[43] Corporate Governance - The company is focused on maintaining strong governance and transparency in its operations[100] - The management team has a diverse background in various sectors, enhancing the company's strategic capabilities[100] - The company has maintained stable shareholding for key executives, with no significant changes reported[99] Environmental Responsibility - The company invested CNY 59.7 million in environmental protection during the reporting period[129] - The company has established a comprehensive waste management strategy, ensuring that all solid waste is legally disposed of and utilized[140] - The company has implemented a continuous monitoring system for waste gas emissions, ensuring real-time data reporting to environmental authorities[142] Employee Engagement and Welfare - The company has focused on employee welfare, providing benefits during holidays and health check-ups, which has positively impacted employee satisfaction and stability[38] - The company has implemented a training program aimed at improving employee skills and overall performance, focusing on quality enhancement and cost reduction[116] Risk Management - The company has established a comprehensive risk management system to enhance financial data analysis and fund usage supervision[126] - The company is addressing market risks by improving product quality and customer service to mitigate competition in the domestic market[92] Shareholder Relations - The company approved a cash dividend of CNY 411,440,750.06, which represents 43.63% of the net profit attributable to ordinary shareholders for the most recent fiscal year[121] - The cumulative cash dividend amount over the last three accounting years is CNY 842,104,437.10, with a cash dividend ratio of 108.10% based on the average net profit during that period[123]

山东省药用玻璃股份有限公司 董事会审计委员会对会计师事务所 2024 年度 履行监督职责情况报告 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上 市公司治理准则》、《国有企业、上市公司选聘会计师事务所管理办法》、 《上海证券交易所上市公司自律监管指引第 1 号——规范运作》和山 东省药用玻璃股份有限公司（以下简称"公司"）的《公司章程》、《董 事会审计委员会工作细则》等规定和要求，董事会审计委员会本着勤 勉尽责的原则，恪尽职守，认真履职。现将董事会审计委员会对中汇 会计师事务所（特殊普通合伙）（以下简称"中汇"）2024 年度履职 评估及履行监督职责的情况汇报如下： 一、2024 年年审会计师事务所基本情况 （一）会计师事务所基本情况 中汇会计师事务所（特殊普通合伙），成立于 2013 年 12 月 19 日， 创立于 1992 年，于 2013 年 12 月转制为特殊普通合伙，注册地址为 杭州市上城区新业路 8 号华联时代大厦 A 幢 601 室，执行事务合伙人 为余强。 截至 2024 年 12 月 31 日，合伙人人数 116 人，注册会计师人数 694 人，签署过证券服务业务审计报告的注 ...

IN --- 山东省药用玻璃股份有限公司 年度募集资金存放与使用情况鉴证报告 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhcpa.cn 目 录 | | 页 次 | | --- | --- | | 一、年度募集资金存放与使用情况鉴证报告 | 1-2 | 二、山东省药用玻璃股份有限公司关于 2024 年度募集资金 存放与使用情况的专项报告 3-10 中国杭州市钱江新城新业路 8号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhcpa.cn ...

证券代码：600529 证券简称：山东药玻 编号：2025-020 山东省药用玻璃股份有限公司 关于 2024 年度募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据中国证监会发布的《上市公司监管指引第2号—上市公司募集资 金管理和使用的监管要求（2022年修订）》（证监会公告〔2022〕15号） 和上海证券交易所发布的《上海证券交易所上市公司自律监管指引第1 号规范运作（2023年12月修订）》（上证发〔2023〕193号）等有关规定， 编制了公司2024年度募集资金存放与使用情况的专项报告。 一、募集资金基本情况 1、实际募集资金金额和资金到账时间 经中国证券监督管理委员会证监许可[2022]1852 号文件《关于核准 山东省药用玻璃股份有限公司非公开发行股票的批复》核准，公司向特 定对象非公开发行人民币普通股(A 股)股票 68,646,366 股，每股面值 1.00 元，发行价格为 27.19 元/股，募集资金总额 1,866,494,691.54 元， 扣除发行费用(不含税)2 ...

根据证监会《上市公司独立董事管理办法》、上海证券交易所《股 票上市规则》、《上市公司自律监管指引第 1 号--规范运作》等要求， 山东省药用玻璃股份有限公司(以下简称"公司")董事会，就公司 2024 年度独立董事孙宗彬、顾维军、陈茂鑫的独立性情况进行评估 并出具如下专项意见: 经核查独立董事孙宗彬、顾维军、陈茂鑫的任职经历以及签署的 相关自查文件，上述人员未在公司担任除独立董事以外的任何职务， 也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不 存在利害关系或其他可能妨碍其进行独立客观判断的关系，因此，公 司独立董事符合《上市公司独立董事管理办法》、《上海证券交易所上 市公司自律监管指引第 1 号--规范运作》中对独立董事独立性的相关 要求。 山东省药用玻璃股份有限公司 董事会 2025 年 4 月 25 日 1 山东省药用玻璃股份有限公司董事会 关于独立董事独立性自查情况的专项意见 ...

山东省药用玻璃股份有限公司 2024 年度监事会工作报告 2024 年监事会全体成员严格按照《公司法》、《证券法》、《上海 证券交易所股票上市规则》等法律法规的要求，结合公司实际情况， 遵循《公司章程》、《监事会议事规则》等相关制度，认真履行监督职 责，对公司股东大会及董事会的召开程序和决策程序、董事会对股东 大会决议的执行情况、高级管理人员的履职情况、公司管理制度执行 情况、公司内部控制情况、定期报告等重大事项的表决程序、公允性、 合法性、合规性等进行了监督检查，在维护公司利益、股东权益及促 进公司规范运作等方面发挥了积极作用。现将公司监事会 2024 年度 主要工作报告如下： 一、报告期内监事会会议情况 报告期内，公司监事会认真履行工作职责，审慎行使《公司章程》 和股东大会赋予的职权，结合公司实际需要，共召开了 5 次监事会， 会议的召集和召开程序符合相关法律、法规的规定，具体情况如下： | 召开会议的次数 | | | 5 | | --- | --- | --- | --- | | 监事会会议情况 | | | 监事会会议议题 | | | | | 审议通过了：公司关于一级耐水药用玻璃瓶项目增 | | 202 ...

关于山东省药用玻璃股份有限公司 非经营性资金占用及其他关联资金往来情况的专项审核说明 中国杭州市钱江新城新业路 8号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhcpa.cn 日 景 | | 页 次 | | --- | --- | | 一、非经营性资金占用及其他关联资金往来情况的专项 | | | 审核说明 | 1-2 | | 二、非经营性资金占用及其他关联资金往来情况汇总表 | | 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road, Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhcpa ...

山东省药用玻璃股份有限公司 董事会审计委员会 2024 年度履职情况报告 山东省药用玻璃股份有限公司（以下简称"公司"）董事会审计 委员会，根据中国证监会《上市公司治理准则》、《上海证券交易所 股票上市规则》、《上海证券交易所上市公司自律监管指引第1号— 规范运作》、《上市公司独立董事管理办法》、《山东省药用玻璃股 份有限公司章程》（以下简称"《公司章程》"）和《公司董事会审 计委员会工作细则》等有关规定，本着勤勉尽责的原则，积极开展工 作，认真履行职责，现将审计委员会2024年度履职情况报告如下: 一、审计委员会基本情况 2023年12月份，为强化董事会决策功能，健全董事会的审计评价 和监督机制，确保董事会对公司财务信息的充分掌握和有效监督，进 一步完善公司治理结构，根据《上海证券交易所股票上市规则》、《上 海证券交易所上市公司自律监管指引第1号—规范运作》、《上市公 司独立董事管理办法》、《公司章程》及其他有关规定，对公司董事 会审计委员会进行补选。 公司第十届董事会第十次会议审议通过了《关于补选公司第十届 董事会各专业委员会委员的议案》，同意选举独立董事孙宗彬先生、 独立董事陈茂鑫先生及外部董事魏其文先 ...